Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238689 | 0.96 | LMNA (0.62) | LMNASMN1; SMN2MAPK1PKMPOLB | |
| SCHEMBL2035293 | 0.89 | LMNA (0.69) | LMNASMN1; SMN2MAPK1PKMPOLB | |
| SCHEMBL28790808 | 0.89 | LMNA (0.59) | LMNASMN1; SMN2MAPK1PKMPOLB | |
| SCHEMBL9493715 | 0.85 | LMNA (0.64) | LMNASMN1; SMN2MAPK1PKMPOLB | |
| SCHEMBL28458158 | 0.84 | SMN1; SMN2 (0.44) | LMNASMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL5850556 | 0.82 | LMNA (0.47) | LMNASMN1; SMN2MAPK1PKMPOLB | |
| SCHEMBL27626350 | 0.82 | LMNA (0.60) | LMNASMN1; SMN2MAPK1PKMPOLB | |
| SCHEMBL3222697 | 0.82 | LMNA (0.60) | LMNASMN1; SMN2MAPK1PKMPOLB | |
| SCHEMBL28399641 | 0.81 | LMNA (0.46) | LMNASMN1; SMN2MAPK1PKMPOLB | |
| SCHEMBL2980601 | 0.80 | LMNA (0.58) | LMNASMN1; SMN2MAPK1PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | claimed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | claimed |
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | claimed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | claimed |
| EP-2088865-A2 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | Jina Pharmaceuticals Inc. (US) | 2009-08-19 | — | — | EP | claimed |
| WO-2008058156-A9 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2008-12-04 | — | — | WO | claimed |
| WO-2008058156-A2 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-0295262-B1 | PHENOLIC RESIN-POLYISOCYANATE BINDER SYSTEMS CONTAINING AN ORGANOHALOPHOSPHATE AND USE THEREOF | ASHLAND OIL INC (US) | 1994-09-07 | — | — | EP | claimed |
| US-4683252-A | Phenolic resin-polyisocyanate binder systems containing an organohalophosphate and use thereof | ASHLAND OIL, INC. (US) | 1987-07-28 | — | — | US | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12454540-B2 | Prodrugs of L-BHDU and methods of treating viral infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-3983064-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983065-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3966662-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966664-A | Solid, rapid-setting, rigid polyurethanes | THE DOW CHEMICAL COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3965073-A | Preparation of rapid setting non-elastomeric polyurethane compositions in the presence of ester-modified polyoxyalkylene compounds | THE DOW CHEMICAL COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
| US-3956221-A | Rapid setting non-elastomeric polyurethane compositions containing a non-hydroxyl containing ester-modified polyoxylkylene compound | THE DOW CHEMICAL COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | SGMS2, SGMS1, PLA2G5 | LMNA 1323/4885SMN1; SMN2 3094/4885MAPK1 4165/4885 |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | SGMS1, SGMS2, GGPS1 | LMNA 1667/4885SMN1; SMN2 3304/4885MAPK1 4152/4885 |
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | ACHE, BCHE, MUSK | LMNA 2268/4885SMN1; SMN2 415/4885MAPK1 4808/4885 |
| US-12454540-B2 | Prodrugs of L-BHDU and methods of treating viral infections | ALKBH3, OGA, ALKBH1 | LMNA 2746/4885SMN1; SMN2 3569/4885MAPK1 2678/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | LMNA 1033/4885SMN1; SMN2 2020/4885MAPK1 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.